Table 1.
Characteristics of AML patient samples
| Sample | Age at diagnosis | Sex | FAB | WHO | Cytogenetics | Blasts | CD34 | Flt3-ITD | NPM1 | CD47-RFI |
| yr | % | % | ||||||||
| 1 | 35 | M | M4 | AML not otherwise specified | inv(3)(q21q26.2),-7 | 70 | 91 | NA | NA | 4.6 |
| 2 | 64 | M | M1 | AML not otherwise specified | normal | 90 | 83 | + | WT | 3.1 |
| 3 | 83 | F | M5a | AML not otherwise specified | +8,+20 | 70 | 0 | NA | NA | 12.4 |
| 4 | 70 | M | M0 | AML not otherwise specified | +13 | 90 | 92 | NA | NA | 17.8 |
| 5 | 72 | F | M1 | AML not otherwise specified | normal | 90 | 27 | NA | NA | 6.7 |
| 6 | 39 | F | M5a | AML not otherwise specified | +8 | 90 | 16 | NA | NA | 4.4 |
| 7 | 45 | F | M1 | AML not otherwise specified | normal | 80 | 70 | NAa | NA | 12.5 |
| 8 | 93 | M | NA | AML not otherwise specified | normal | NA | 22 | + | mut | 11.7 |
| 9 | 51 | M | NA | AML with multilineage dysplasia following a MDS | +8 | 30 | 3 | − | WT | 5.7 |
| 10 | 51 | M | M5 | AML not otherwise specified | normal | 29 | 1 | + | mut | 20.2 |
| 11 | 23 | M | M0 | AML not otherwise specified | +i(8)(q10)/-8,+r1/-8,+r1,+r2 | 28 | 96 | + | WT | 7.4 |
| 12 | 52 | F | M2 | AML not otherwise specified | +8 | 95 | 70 | + | WT | 9.4 |
| 13 | 47 | F | M6 | AML not otherwise specified | normal | 40 | 6 | − | NA | 6.2 |
| 14 | 70 | M | M0 | AML not otherwise specified | +8 | 90 | 84 | NA | NA | 5.5 |
| 15 | 20 | F | M4 | AML not otherwise specified | normal | 50 | 14 | NA | NA | 4.1 |
| 16 | 63 | F | M4 | AML not otherwise specified | normal | 40 | 6 | − | mut | 7.9 |
| 17 | 61 | M | M4 | AML not otherwise specified | normal | 90 | 15 | + | NA | 3.9 |
| 18 | NA | NA | NA | NA | NA | NA | 76 | NA | NA | 16.3 |
| 19 | 56 | F | M5a | AML not otherwise specified | NA | 95 | 9 | NA | NA | 15 |
| 20 | 80 | F | NA | AML with multilineage dysplasia following a MDS | t(X;3)(q22;p26),add(7)(q22)/idem,del(16)(q22) | 95 | 3 | + | WT | 12.7 |
| 21 | 83 | M | M2 | AML with multilineage dysplasia following a MDS | +3,+9,+12 | 90 | NA | NA | NA | 12 |
| 22 | 69 | M | M0 | AML with multilineage dysplasia following a MDS | -Y | 97 | 93 | NA | NA | 14.2 |
| 23 | 67 | M | M1 | AML not otherwise specified | NA | 80 | 83 | + | WT | 13.1 |
| 24 | 47 | F | M1 | AML not otherwise specified | normal | 85 | 1 | + | NA | NA |
| 25 | 60 | F | M2 | AML not otherwise specified | normal | 23 | 96 | − | WT | NA |
| 26 | 40 | M | M4 | AML not otherwise specified | 46,XY,add(8)(q24.3),t(16;16)(p13.1;q22)[20].ish t(16;16)(3′ CBFB+;5′ CBFB+)[2] and INV (16) | 66 | 99 | NA | NA | 10.6 |
| 27 | 46 | M | M5b | AML not otherwise specified | normal | 90 | 1 | + | mut | 3.6 |
| 28 | 33 | M | M1 | AML not otherwise specified | 46,XY,ider(7)(q10)del(7)(q21) | >90 | 99 | NA | NA | 6.3 |
| 29 | 74 | M | M0 | AML not otherwise specified | NA | 83 | >95 | NA | NA | NA |
F, female; FAB, French-American-British; M, male; mut, mutated; NA, not available; RFI, relative fluorescence intensity compared with unstained (no Ab added).
a
Inconclusive results.